Cell line · CVCL_0530
Papers61
1 to 20 of 61
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Activation of Bradykinin B2 Receptors in Astrocytes Stimulates the Release of Leukemia Inhibitory Factor for Autocrine and Paracrine Signaling. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| STAG2 loss in Ewing sarcoma alters enhancer-promoter contacts dependent and independent of EWS::FLI1. | EMBO Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer's disease. | Mol Neurodegener | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. | Br J Pharmacol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. | Cell Rep | 2022 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| pncCCND1_B Engages an Inhibitory Protein Network to Downregulate CCND1 Expression upon DNA Damage. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. | J Immunother Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics profiling of Ewing sarcoma cell lines. | 2021 | Cellosaurus cites it | DOI | ||
| The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. | Cell | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment. | Cells | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma. | Br J Cancer | 2019 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0530/papers